Specifically, GENERA was applied to the angiotensin-converting enzyme 2 (ACE2) target,which is implicated in many pathological conditions, including COVID-19.The ability of GENERA to de novo design promisingcandidates for a specific target was assessed using two docking programs,PLANTS and GLIDE. This evidence concerns the gene ACE2 and COVID-19.